Pollok K E, Williams D A
Herman B Wells Center for Pediatric Research, Riley Hospital for Children, Indiana University School of Medicine, 1044 West Walnut Street, Indianapolis, IN 46202-5525, USA.
Curr Opin Mol Ther. 1999 Oct;1(5):595-604.
A transduction strategy has been developed, using fibronectin (FN)-assisted retroviral-mediated gene transfer, based on the observation that hematopoietic stem and progenitor cells bind to specific adhesion domains of fibronectin, via the integrins, very late antigen-4 (VLA-4)alpha 4 beta 1 and very late antigen-5 (VLA-5)alpha 5 beta 1. Retrovirus-mediated transduction on a recombinant FN fragment, FN CH-296, containing binding sites for VLA-4 and VLA-5, separated by type III repeats 12 to 14, makes it possible to efficiently target hematopoietic stem and progenitor cells and T-lymphocytes due to colocalization of target cells and retrovirus particles. These gene therapy strategies are applicable to the potential treatment of a variety of acquired and inherited immune disorders.
基于造血干细胞和祖细胞通过整合素、极晚期抗原-4(VLA-4)α4β1和极晚期抗原-5(VLA-5)α5β1与纤连蛋白的特定粘附结构域结合这一观察结果,已开发出一种转导策略,即使用纤连蛋白(FN)辅助的逆转录病毒介导的基因转移。在重组FN片段FN CH-296上进行逆转录病毒介导的转导,该片段包含VLA-4和VLA-5的结合位点,由12至14个III型重复序列隔开,由于靶细胞和逆转录病毒颗粒的共定位,使得有效靶向造血干细胞、祖细胞和T淋巴细胞成为可能。这些基因治疗策略适用于多种获得性和遗传性免疫疾病的潜在治疗。